Grade III glioma

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…

This study tests a more intense treatment for a fast-growing type of brain cancer called IDH wildtype glioma. It combines higher doses of radiation with the chemotherapy drug temozolomide to try to stop the tumor from growing longer. The trial will enroll 40 adults with this spec…

This study looks at how safe and effective temozolomide (brand name Amitzo) is for people with aggressive brain tumors (grade III and IV gliomas). Researchers are tracking 100 patients to see how often liver injury occurs and to monitor other side effects. The goal is to better u…

This early-phase study tests the drug lorlatinib in children and young adults (ages 1 to 21) with newly diagnosed high-grade glioma, a fast-growing brain tumor, that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor…

This phase 2 trial is testing whether combining the drug ONC201 with other treatments (like paxalisib or a cancer-killing virus called DNX-2401) can help children and young adults with diffuse midline gliomas, a rare and aggressive brain cancer. The study enrolls 360 participants…

This early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose…

This early-phase trial tests a combination of two drugs—D2C7-IT and 2141-V11—for adults with recurrent malignant glioma, a serious brain cancer. The drugs are delivered directly into the tumor and nearby lymph areas. The main goal is to check safety and find the right dose in 90 …

This study tests whether adding two different drug combinations after radiation can help children and young adults (up to age 21) with high-grade gliomas, including DIPG, live longer. One group receives ribociclib plus everolimus; another gets ribociclib plus temozolomide. The go…

This early-phase trial is testing a new type of immunotherapy called anti-GARP CAR T-cell therapy for people with recurrent high-grade gliomas (aggressive brain tumors). Researchers will take a patient's own immune cells, modify them in the lab to target a protein called GARP fou…

This study tests a gene therapy (HSV-tk) plus valacyclovir, along with radiation and chemotherapy, in people whose glioblastoma or high-grade astrocytoma has returned. The goal is to see if this combination can improve survival. About 62 participants will receive the treatment di…

This study tests whether a special PET scan using GA-68 PSMA-11 can tell the difference between a returning brain tumor and changes caused by previous treatment. About 25 adults with grade 3 or 4 glioma who are already scheduled for surgery will receive the scan beforehand. If su…

This study tests whether a custom-made video, showing symptoms and side effects based on each patient's own brain scan, can lower anxiety for people with brain tumors and their caregivers during radiation treatment. About 117 patients with newly diagnosed glioma and their caregiv…

This study tests a remote cognitive rehabilitation program for adults with slow-growing brain tumors (grade 2 or 3 glioma) who often struggle with memory, attention, and thinking. About 187 participants will either receive the program or standard care. The goal is to see if the p…

This study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…

This early phase 1 trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug gets into the brain tumor and blood, and whether it affects cholesterol-related pathways. Par…

This study tests a new type of MRI scan that uses a special substance (hyperpolarized 13C pyruvate) to see how brain tumors use energy. Researchers want to know if this scan is safe and can show changes in tumor metabolism over time. About 300 people with low-grade gliomas will b…